Answers are grounded in this paper and cite their sources.
Background: The current guidelines lack details on the potential variations in clinical features in Sézary syndrome (SS) patients. Recently, a clinical score has been proposed based on three main presentations of erythroderma, with potential prognostic value.[1] Methods: Patients with Stage IV SS were prospectively treated and followed at a single-center university-based institution from January 1st, 2017, to November 2023. Patients were classified based on the recently proposed classification (E0 sub-erythroderma, E1 erythematous, E2 infiltrative, E3 melanoderma). Kaplan-Meier method and Cox regressions were employed to assess overall survival differences. Results: After a median follow-up of 52 months, data on 21 stage IVA1 patients were available. The cohort displayed a male prevalence (66.7%), with a median age of 73 (range 28-88). Eighteen out of 21 patients (85.7%) had at least one other comorbidity, and 5/21 (23.8%) had a previous diagnosis of patch/plaque mycosis fungoides. Pruritus was present in 18 patients (85.7%). The median CD4+CD26-/CD7- count value at diagnosis was 3337 (range 100-14500). Four out of 21 patients (19.0%) showed large cell transformation. The mean total number of lines of therapies was 5 (range 2-9), with oral retinoids (85.7%), ECP (81.0%), and mogamulizumab (42.9%) being the most common. In the initial assessment, 12 patients were categorized as E0 (57.1%), 8 as E1 (38.1%), and 1 as E2 (4.8%). Over the follow-up period, 6 patients (28.6%) transitioned from sub-erythroderma (E0) to erythematous erythroderma (E1). Additionally, 6 patients (28.6%) developed melanoderma (E3), comprising 3 initially classified as E0 and the remaining 3 as E1. The sole E2 patient maintained consistent clinical features throughout the follow-up duration. According to the log-rank test, patients with melanoderma (E3) exhibited significantly inferior survival rates compared to non-melanodermic patients, with 48-month survival rates of 67.1% versus 25.0% (p=0.027). Cox regression analysis underscored the negative association between melanoderma (E3) and survival (3.72 HR, 95% CI 1.06-13.02, p=0.040), irrespective of other variables in the study. Conclusions: Patients manifesting melanoderma (E3) demonstrate compromised overall survival, substantiating the adverse influence of melanoderma on prognosis. Despite the study's limited scale, the prospective data yield valuable insights applicable to clinical practice. References[1]Roccuzzo G, Giordano S, Avallone G, et al. Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System. Cells. 2022;11(3):333. Published 2022 Jan 20. doi:10.3390/cells11030333.
No takes yet. Share an insight, caveat, or question.
Roccuzzo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: